Granahan Investment Management LLC Has $3.41 Million Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Granahan Investment Management LLC cut its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 13.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,617,178 shares of the medical instruments supplier’s stock after selling 248,251 shares during the quarter. Granahan Investment Management LLC’s holdings in Harvard Bioscience were worth $3,412,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of HBIO. Barclays PLC lifted its position in Harvard Bioscience by 304.4% during the third quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 44,150 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Harvard Bioscience by 63.0% during the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock worth $79,000 after purchasing an additional 11,397 shares during the period. Williams & Novak LLC acquired a new stake in Harvard Bioscience during the 4th quarter worth approximately $209,000. AMH Equity Ltd boosted its stake in Harvard Bioscience by 4.7% in the 4th quarter. AMH Equity Ltd now owns 2,500,000 shares of the medical instruments supplier’s stock valued at $5,275,000 after purchasing an additional 111,132 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Harvard Bioscience by 11.1% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 200,032 shares of the medical instruments supplier’s stock valued at $422,000 after buying an additional 20,026 shares in the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Stock Performance

NASDAQ:HBIO opened at $0.32 on Friday. The company has a market cap of $14.15 million, a price-to-earnings ratio of -0.97 and a beta of 1.44. Harvard Bioscience, Inc. has a fifty-two week low of $0.29 and a fifty-two week high of $3.60. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06. The stock has a fifty day moving average price of $0.50 and a 200-day moving average price of $1.43.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on HBIO shares. StockNews.com started coverage on Harvard Bioscience in a report on Tuesday, May 6th. They set a “hold” rating for the company. Benchmark dropped their price objective on shares of Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating for the company in a research note on Monday, March 24th. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of Harvard Bioscience in a report on Wednesday, April 9th.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.